What is Zacks Small Cap’s Forecast for PLX FY2025 Earnings?

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Investment analysts at Zacks Small Cap lowered their FY2025 earnings per share estimates for shares of Protalix BioTherapeutics in a research report issued to clients and investors on Tuesday, February 3rd. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.04) for the year, down from their prior forecast of $0.02. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Small Cap also issued estimates for Protalix BioTherapeutics’ Q4 2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.06) EPS and FY2027 earnings at $0.08 EPS.

Separately, HC Wainwright dropped their price objective on shares of Protalix BioTherapeutics from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Protalix BioTherapeutics currently has an average rating of “Buy” and a consensus target price of $12.00.

Protalix BioTherapeutics Price Performance

PLX stock opened at $2.91 on Thursday. The company has a market cap of $234.03 million, a price-to-earnings ratio of -22.38 and a beta of -0.25. The company has a fifty day moving average price of $1.95 and a 200 day moving average price of $1.92. Protalix BioTherapeutics has a 12 month low of $1.32 and a 12 month high of $3.10.

Insider Transactions at Protalix BioTherapeutics

In other news, CEO Dror Bashan acquired 56,000 shares of Protalix BioTherapeutics stock in a transaction that occurred on Friday, December 19th. The stock was purchased at an average price of $1.81 per share, for a total transaction of $101,360.00. Following the completion of the transaction, the chief executive officer directly owned 188,516 shares in the company, valued at approximately $341,213.96. This trade represents a 42.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Protalix BioTherapeutics

A number of large investors have recently modified their holdings of PLX. R Squared Ltd acquired a new stake in shares of Protalix BioTherapeutics in the 4th quarter valued at approximately $26,000. NewEdge Advisors LLC purchased a new position in Protalix BioTherapeutics in the first quarter worth $39,000. BNP Paribas Financial Markets lifted its holdings in Protalix BioTherapeutics by 126.5% in the third quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock valued at $34,000 after acquiring an additional 8,498 shares during the period. Virtu Financial LLC acquired a new stake in Protalix BioTherapeutics in the third quarter valued at $37,000. Finally, Cascade Financial Partners LLC purchased a new stake in shares of Protalix BioTherapeutics during the 2nd quarter worth $25,000. 16.53% of the stock is owned by hedge funds and other institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.